May 31, 2021
OncoBone is pleased to announce partnering with BiomimX®, a technology-driven company developing innovative pre-clinical solutions based in Milan, Italy. The partnering includes OncoBone to provide its expertise to support BiomimX in expanding its visibility and client-base for its specialized screening services building upon uKnee, a model of pathological human joint on chip.
BiomimX is a pioneer in the development of functional predictive models of human organs and pathologies that will improve the way to test drugs and medical devices. Integrating 3D cell culture and mechanical stimulation, BiomimX offers the next generation organ-on-chip technology, allowing to recapitulate the physiological or pathological states of human organs with accurate precision. BiomimX’s portfolio includes uKnee, the first 3D in vitro pathological model of human Osteoarthritic (OA) joint to profile safety and efficacy of pharmaceutical products and intra-articular medical devices.
As part of the partnership OncoBone will represent BiomimX in the forthcoming events BIO Digital on June 14 – 18, 2021 and American Society for Bone and Mineral Research (ASBMR) Annual meeting on October 1 – 4, 2021.